Comparison of ATG-thymoglobulin with atg-fresenius in patients with hematological malignancies who undergo allogeneic hematopoietic stem cell transplantation: a propensity score-matched analysis
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06267-4 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Hematology, 2025. Verfasst von Hanyue Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Antilymphocyte Serum, Hematologic Neoplasms, Propensity Score. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We retrospectively compared the outcomes of 166 patients with hematological malignancies who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) using ATG-Thymoglobulin (ATG-T) at 10 mg/kg or ATG-Fresenius (ATG-F) at 20 mg/kg. Propensity score matching (PSM) analysis was applied, with 44 patients assigned to each group. The ATG-T group showed a trend toward a higher incidence of bacterial infections (72.7% vs. 65.9%, P = 0.064). Additionally, the ATG-T group had a significantly higher incidence of other viral infections, including BK virus and herpes zoster virus (40.9% vs. 15.9%, P = 0.003), compared to the ATG-F group. Furthermore, the ATG-F group experienced a lower incidence of high fever (4.5% vs. 50.0%, P < 0.001) and reduced ATG treatment costs [¥ 45100 (28700–82000) vs. ¥ 56250 (38000–85000), P < 0.001] compared to ATG-T. The incidences of acute GVHD, grade III-IV aGVHD, grades of aGVHD, chronic GVHD, 3-year overall survival (OS), transplantation-related mortality (TRM), non-relapse mortality (NRM), disease-free survival (DFS), and GVHD-free and relapse-free survival (GRFS) were similar between the ATG-T and ATG-F groups. In conclusion, our study suggests that ATG-F is superior to ATG-T in terms of viral infections, fever rate, and treatment cost.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Hematology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. zhouyh83@mail.sysu.edu.cn.
- Department of Gastroenterology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China. zhouyh83@mail.sysu.edu.cn.
- Department of Hematology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. lixudong@mail.sysu.edu.cn.
- Department of Hematology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. longb3@mail.sysu.edu.cn.
Zitieren
APA
Zhang, H., Zhou, Y., Zhao, K., Cui, J., Zhang, X., Wen, R., Sun, Y., Li, X., & Long, B. (2025). Comparison of ATG-thymoglobulin with atg-fresenius in patients with hematological malignancies who undergo allogeneic hematopoietic stem cell transplantation: a propensity score-matched analysis. Annals of Hematology. https://doi.org/10.1007/s00277-025-06267-4
Vancouver
Zhang H, Zhou Y, Zhao K, Cui J, Zhang X, Wen R, et al. Comparison of ATG-thymoglobulin with atg-fresenius in patients with hematological malignancies who undergo allogeneic hematopoietic stem cell transplantation: a propensity score-matched analysis. Annals of Hematology. 2025. doi:10.1007/s00277-025-06267-4
BibTeX
@article{Zhang2025,
author = {Zhang, Hanyue and Zhou, Yuhang and Zhao, Kui and Cui, Jiaqi and Zhang, Xiangzhong and Wen, Ruijuan and Sun, Yanling and Li, Xudong and Long, Bing},
title = {Comparison of ATG-thymoglobulin with atg-fresenius in patients with hematological malignancies who undergo allogeneic hematopoietic stem cell transplantation: a propensity score-matched analysis},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06267-4}
}
EUVIMED